Drug Profile

MA 4604

Alternative Names: MA-4604

Latest Information Update: 13 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Ferring Pharmaceuticals
Developer Maipl Therapeutics
Class Small molecules
Mechanism of Action Prostaglandin F2alpha receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Endometriosis

Most Recent Events

20 May 2025 Preclinical trials in Endometriosis in USA (PO)
20 May 2025 Pharmacodynamics data from a phase I trial in Endometriosis released by Maipl Therapeutics
20 May 2025 Maipl Therapeutics plans a phase I trial for Endometriosis in 2Q 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com